Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated
AssigneeQLT Inc.
InventorsH. Andrew Strong, Suzanne Cadden
Life of this patent
Estimating the term…
Abstract
Disclosed herein are therapeutic regimens for treating or ameliorating a visual disorder associate with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative or a pharmaceutically acceptable composition comprising a synthetic retinal derivative according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.
Claims57
1-33. (canceled)
A method for treating a patient suffering from the loss or impairment of vision caused by a retinoid deficiency disorder, comprising the steps of:
- a) administering to the patient an initial therapeutically effective dose of a synthetic retinal derivative that provides replacement for endogenously produced 11-cis-retinal,
- b) refraining from administering to the patient an additional therapeutically effective dose of synthetic retinal derivative for a resting interval of at least 1 month,
- c) administering to the patient an additional therapeutically effective dose of a synthetic retinal derivative.
A method for treating a patient suffering from the loss or impairment of vision caused by a retinoid deficiency disorder, comprising the steps of:
- d) administering to the patient an initial therapeutically effective dose of a synthetic retinal derivative that provides replacement for endogenously produced 11-cis-retinal,
- e) refraining from administering to the patient an additional dose of a synthetic retinal derivative until the improvement or restoration of the patient's vision diminishes,
- f) administering to the patient another therapeutically effective dose of a synthetic retinal derivative.
A method for treating a patient suffering from loss or impairment of vision due to inherited mutations in RPE65 or LRAT genes associated with Leber congenital amaurosis or Retinitis Pigmentosa, comprising the steps of:
- g) administering to the patient an initial therapeutically effective dose of a synthetic retinal derivative that provides replacement for endogenously produced 11-cis-retinal,
- h) refraining from administering to the patient an additional therapeutically effective dose of synthetic retinal derivative for a resting interval of at least 1 month,
- i) administering to the patient an additional therapeutically effective dose of a synthetic retinal derivative.
Dependencies are inferred from the claim text.